Clinical Trial

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Name: A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma — clinical trial record (NCT07106671)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Record status

This record was last updated August 6, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.

Trial Details

NCT Number	NCT07106671
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	CRS - Cytokine Release Syndrome, Myeloma
Enrollment	20 participants
Start Date	2025-08-10
Primary Completion	2026-08-01 (estimated)
Study Completion	2027-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-06